

Aurobindo diabetes generic gets US FDA nod

February 4, 2014 | Regulatory | By BioSpectrum Bureau



Singapore: Aurobindo Pharma has received US FDA approval for Repaglinide tablets, the generic equivalent of Novo Nordisk's Prandin Tablets.

The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The market size of the product is estimated to be \$274 million for the 12 months ending November 2013, according to IMS Health.